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Minimal phenotyping refers to the reliance on the use of a small number of self-reported items for 
disease case identification, increasingly used in genome-wide association studies (GWAS). Here we 
report differences in genetic architecture between depression defined by minimal phenotyping and 
strictly defined major depressive disorder (MDD): the former has a lower genotype-derived 
heritability that cannot be explained by inclusion of milder cases, and a higher proportion of the 
genome contributing to this shared genetic liability with other conditions than strictly defined 
MDD. GWAS based on minimal phenotyping definitions preferentially identifies loci that are not 
specific to MDD, and though it generates highly predictive polygenic risk scores, the predictive 
power can be explained entirely by large sample sizes rather than specificity for MDD. Our results 
show that reliance on results from minimal phenotyping may bias our views of the genetic 
architecture of MDD and impede our ability to identify pathways specific to MDD. 
 
A key requisite for robust identification of genetic risk loci underlying psychiatric disease is the use of an 
appropriately large sample. However, the high cost of phenotyping limits sample collection1. One solution 
for reducing the burden of case identification is to use information from hospital registers2 or individuals’ 
self-reported symptoms, help-seeking, diagnoses or medication. We refer to the latter strategy as 
“minimal phenotyping”, as it minimizes phenotyping costs and reduces data to a single or few self-
reported answers. 
However, apart from detecting more GWAS loci3-5 (Supplementary Table 1), the consequences of 
sacrificing symptomatic information for genetic analyses have rarely been investigated. The consequences 
may be particularly important for major depressive disorder (MDD) because of its phenotypic and likely 
etiological heterogeneity6, high degree of comorbidity with other psychiatric diseases7, and substantial 
discrepancies between self-assessment using symptom scales and diagnoses made with full diagnostic 
criteria8. While a majority of the population self-identify as having one or two depressive symptoms at 
any one time, only between 9% and 20% of the population have sufficient symptoms to meet criteria for 
lifetime occurrence of MDD8-10. Furthermore, there are high rates of false positives when diagnoses are 
made without applying diagnostic criteria12, and antidepressants are prescribed for a wide range of 
conditions other than MDD13-15. As such, a cohort of MDD cases obtained either through the use of self-
report of illness or prescribed treatment may yield a sample that is not representative of the clinical 
disorder, but enriched in those with non-specific sub-clinical depressive symptoms and depression 
secondary to a comorbid disease.  
By comparing the genetic architecture of minimal phenotyping definitions of depression with 
those using full diagnostic criteria for MDD in UK Biobank16, a community-based survey of half a 
million men and women, we assess the implications of a minimal phenotyping strategy for GWAS in 
5 
 
MDD. We find that MDD defined by minimal phenotyping has a large non-specific component, and if 
GWAS loci from these definitions are chosen for follow-up molecular characterization, they may not be 
informative about biology specific to MDD.  
 
 
Results 
 
Definitions of depression in UK Biobank. We identified five ways that MDD can be defined in UK 
Biobank. First, self-reports of seeking medical attention for depression or related conditions provide 
“Help-seeking” definitions of MDD (referred to as “broad depression” in a previous GWAS3). Second, 
participants are diagnosed with “Symptom-based” MDD if, in addition to meeting help-seeking criteria, 
they report ever experiencing one or more of the two cardinal features of depression (low mood or 
anhedonia) for at least two weeks17. Third, a “Self-Report” definition of MDD is based on participants’ 
self-reports of all past and current medical conditions to trained nurses. Fourth, an electronic medical 
record (“EMR”) definition is derived from ICD10 primary and secondary illness codes in electronic 
health records. Finally, a “CIDI-based” diagnosis of lifetime MDD is available from subjects who 
answered an online “Mental Health Follow-up” questionnaire (MHQ)18 based on the Composite 
International Diagnostic Interview Short Form (CIDI-SF)19, which included DSM-5 criteria for MDD 
(Supplementary Note, Supplementary Fig. 1, and Supplementary Table 2). None of the definitions uses 
trained interviewers applying structured clinical interviews, and only the last applies operationalized 
criteria including symptoms, length of episode (more than two weeks) and impaired social, occupational 
or educational function. From hereon we refer to definitions one to three as ‘minimal’, the fourth as 
“EMR-based”, and the fifth as ‘strictly’ defined MDD (Supplementary Note). We also included a 
category of participants who met the help-seeking based definition (part of “broad depression” in Howard 
et al.3) but failed to meet the symptom-based definition (as they had neither of the two cardinal symptoms 
of depression: depressed mood or a loss of interest or pleasure in daily activities for more than two 
weeks). This group we refer to as “Non-MDD” (described in detail in the Supplementary Note and 
Supplementary Table 3). Figure 1 outlines the different diagnostic categories and the numbers of samples 
that each contains.  
All definitions are based on recall of episodes or symptoms of depression by participants in the 
UK Biobank. As priming of recall by current mood affects the reliability of such reports20-22, we 
emphasize that each definition is noisy, and can be interpreted as being enriched for individuals truly 
fulfilling its criteria. We explore the further characteristics of all definitions and considerations in their 
genome-wide association analyses (GWAS) in the Supplementary Note, Supplementary Figures 2-5, and 
Supplementary Tables 2-11.  
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Minimal phenotyping definitions of depression are epidemiologically different from strictly defined 
MDD. We assessed whether known risk factors for MDD were similar between definitions of 
depression26. Figure 2a-g shows the mean effect (odds ratio, OR) with confidence intervals of each of the 
following: sex27,28, age29, educational attainment30-32, socio-economic status33, neuroticism28,34, experience 
of stressful life events in the two years leading up to the baseline assessment, and cumulative traumatic 
life events preceding assessment35,36 (Supplementary Note and Supplementary Table 12). Estimates of the 
risk factor effect sizes differed substantially, and often highly significantly, as shown by the confidence 
intervals in Figure 2. These may reflect differences in methods of ascertainment, or underlying pathology, 
between definitions of depression. Next we asked whether differences in risk factors could be used to 
classify definitions of depression. We applied a clustering algorithm and found that all minimal 
phenotyping definitions of depression cluster separately from strictly defined MDD (Fig. 2h). 
 
Minimal definitions of depression are not just milder or noisier version of strictly defined MDD. 
Depression defined by minimal phenotyping has lower SNP-based heritabilities (h2SNP) than more strictly 
defined definitions (Fig. 3a). Self-report (SelfRepDep h2SNP = 11%, s.e. = 0.85%) and help-seeking based 
definitions (Psypsy h2SNP = 13%, s.e. = 1.18%; GPpsy h2SNP = 14%, s.e. = 0.81%) have heritabilities of 
15% or less. By contrast, strictly defined MDD (LifetimeMSuDD) has a much higher h2SNP of 26% (s.e. = 
2.15%); imposing the further criterion of recurrence brings the h2SNP up to 32% (s.e. = 2.56%). Other 
definitions have intermediate h2SNP. All h2SNP estimates were estimated on the liability scale using 
PCGCs23 (Supplementary Note), and the trend holds regardless of the method used23,37-39 (Supplementary 
Note and Supplementary Table 13). We further verified that the trend cannot be explained by potential 
case prevalence misestimations (Fig. 3b, Supplementary Note, Supplementary Fig. 3, and Supplementary 
Table 13), and was not affected by regions of high linkage-disequilibrium or complexity40 
(Supplementary Note and Supplementary Fig. 3). We compared h2SNP estimates from previous studies of 
MDD4,41,42 (Supplementary Fig. 6) with our results, and found that they fit squarely into the trend we 
observe: the less strict the criteria used to diagnose MDD, the lower the h2SNP.  
We examined the role of a number of additional factors for the lower h2SNP of minimal 
phenotyping definitions of MDD. First, minimal phenotyping definitions do not simply have a higher 
environmental contribution to MDD than the stricter definitions. When we assessed h2SNP in MDD cases 
with high and low exposure to environmental risk factors44, we found that minimal phenotyping 
definitions of depression (GPpsy, SelfRepDep) show no significant difference between exposures, similar 
to or lower than strictly defined MDD (LifetimeMDD and MDDRecur) (Supplementary Note and 
Supplementary Table 14). Second, the minimal phenotyping definitions do not merely include milder 
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cases of MDD as previously hypothesized43. Inclusion of milder cases is equivalent to lowering the 
threshold for disease liability in the population above which “cases” for MDD are defined. Under the 
liability threshold model45, this does not reduce the h2SNP (Supplementary Note and Extended Data Fig. 1). 
Instead, we show through simulations that the lower h2SNP of minimal phenotyping definitions of 
depression may be due to misdiagnosis of controls as cases of MDD, and misclassifications of those with 
other conditions as cases of MDD (Extended Data Figs. 1 and 2).  
 
Genetic correlations between definitions of depression and other diseases. We found that the genetic 
correlation (rG) between minimal and strictly defined MDD includes a large proportion of non-specific 
liability to mental ill health. The rG between GPpsy (minimal defined MDD) and LifetimeMDD (strictly 
defined MDD) is 0.81 (s.e. = 0.03), significantly different than unity (Fig. 3c,d, Supplementary Table 15, 
Supplementary Fig. 6, and Supplementary Note). One interpretation of this finding is that the correlation 
represents shared genetic liability to MDD4,5. However, the majority of the genetic liability of 
LifetimeMDD due to GPpsy (approximately rG2 = 0.812 = 66%) is shared with the No-MDD definition, 
GPNoDep, as the genetic liability of GPNoDep explains approximately 70% of the genetic liability of 
GPpsy (rG = 0.84, s.e. = 0.05), and 34% of that of LifetimeMDD (rG = 0.58, s.e. = 0.08).  
We next examined rG between different definitions of MDD and comorbid diseases, using cross-
trait LDSC46 to estimate rG with neuroticism and smoking (Extended Data Fig. 3 and Supplementary 
Tables 16 and 17) in UK Biobank, as well as with all psychiatric conditions in the Psychiatric Genomics 
Consortium (PGC)47, including PGC1-MDD42 and depression defined in 23andMe4 (Supplementary Table 
1). Figure 4a and Supplementary Table 18 show few differences in rG estimates between other psychiatric 
disorders and the different definitions of MDD in UK Biobank, consistent with previous reports48.   
Similar rG estimates can result from different genetic architectures, indexed by the extent to 
which genetic liability is spread across the genome. We estimated local rGL and percentage genome 
contribution to total rGT using rho-HESS49 (Methods and Fig. 4b). 65.8% (s.e. = 0.6%), 37.1% (s.e. = 
4.5%) and 42.7% (s.e. = 2.3%) of the genome explains 90% of the rGT between strictly defined MDD 
(LifetimeMDD) and neuroticism, bipolar disorder, and schizophrenia, respectively. In comparison, 80.2% 
(s.e. = 0.6%), 47.3% (s.e. = 2.4%) and 46.8% (s.e. = 0.2%) of the genome is needed to explain the same 
percentage of rGT between help-seeking based GPpsy and the same conditions (Fig. 4c). In other words, 
minimal phenotyping definitions of depression share more genetic loci with other psychiatric conditions 
than strictly defined MDD does. 
Previous work4 reported that depression defined through minimal phenotyping shows enrichment 
of h2SNP in regions of the genome encoding genes specifically and highly expressed in central nervous 
system (CNS) tissues represented in GTEx50. We assessed this in the definitions of depression in UK 
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Biobank using LDSC-SEG51. As shown in Figure 5, neither strictly defined MDD (LifetimeMDD) nor 
MDD defined based on structured clinical assessments in PGC1-MDD show significant CNS 
enrichments, even though larger and more heterogeneous cohorts do (Methods, Supplementary Note, 
Supplementary Table 1, and Extended Data Fig. 4). Notably, minimal phenotyping definition GPpsy 
shows a significant CNS enrichment, as does the non-MDD help-seeking definition GPNoDep, 
neuroticism, smoking, and other disorders in the PGC47 such as schizophrenia53 and bipolar disorder54. 
Our analysis shows that the degree of CNS enrichment does not relate to the strictness of the definition of 
MDD, and is neither sufficient nor valid evidence that any particular definition of depression better 
represents MDD, or captures the biological mechanisms behind MDD.  
 
GWAS hits from minimal phenotyping are not specific to MDD. We next examined the specificity of 
action of individual genetic loci found in GWAS of each definition of MDD. We found that the help-
seeking definitions gave the greatest number of genome-wide significant loci (27 from GPpsy and 
Psypsy, Supplementary Table 10) in GWAS, consistent with their larger sample sizes and statistical 
power for finding associations. We examined whether these loci could be detected in strictly defined 
MDD. Of the 27 loci from minimal phenotyping definitions, 10 showed significant effects (at P < 0.05 
after multiple testing correction for 27 loci) on LifetimeMDD, despite the latter’s much smaller sample 
size, consistent with the hypothesis that risk loci for minimal phenotyping MDD also act in strictly 
defined MDD. However, all 10 loci also showed significant effects in neuroticism, smoking, 
schizophrenia, or the no-MDD help-seeking condition (GPNoDep, Supplementary Table 19). 
Furthermore, all significant SNPs in minimal phenotyping definitions of depression have the same 
directions of effect on non-MDD phenotypes (Fig. 6).  
We found the same pattern of results when we used loci identified from a minimal phenotyping 
strategy in an independent study by 23andMe that used a minimal phenotyping definition4. Of the 17 loci, 
ten replicated in GPpsy (at P < 0.05, after multiple testing correction for 17 loci) and three replicated in 
LifetimeMDD. All significant SNPs have the same directions of effect on neuroticism, smoking or 
schizophrenia (Extended Data Fig. 5 and Supplementary Table 20) and are therefore not specific to MDD, 
consistent with our analysis of minimal phenotyping definitions in UK Biobank. In summary, GWAS of 
minimal phenotyping definitions of depression primarily enables discovery of pathways that are shared 
with other conditions. It is not currently possible to assess the specificity of GWAS loci from strictly 
defined MDD in the same way, given the sample size of strictly defined MDD remains relatively small, 
and GWAS hits relatively few.  
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Out-of-sample prediction of MDD. Finally, we explored how well the definitions of depression in UK 
Biobank predict strictly defined, CIDI-based MDD in independent cohorts, using data from 23 MDD 
cohorts in the latest data freeze from the MDD Working Group of the Psychiatric Genomics Consortium 
(PGC29-MDD5,52; Supplementary Note, Supplementary Table 21, and Supplementary Fig. 7). We 
constructed polygenic risk scores (PRS) on each definition of depression in UK Biobank (Methods) and 
examined their prediction in each of the PGC29-MDD cohorts. Of note, PRS from all definitions of 
depression in UK Biobank, whether minimally or strictly phenotyped, accounted for a small proportion of 
variation in disease status in PGC29-MDD (Supplementary Table 22). We observed the following 
features.  
First, PRS obtained using the full sample of GPpsy performed best at predicting MDD status in 
independent cohorts from PGC29-MDD (Fig. 7a, Nargelkerke’s r2 = 0.018, AUC = 0.56 at P value 
threshold of 0.1; Extended Data Fig. 6). However, when equal sample sizes were used (randomly down-
sampled to 50,000 and case prevalence of 0.15; Methods), GPpsy no longer performed best at predicting 
MDD status in PGC29-MDD cohorts (Fig. 7b). Rather, PRS from the strictly defined CIDI-based MDD 
(LifetimeMDD) best predicted MDD disease status (Nargelkerke’s r2 = 0.0027, AUC = 0.52 at P value 
threshold of 0.1; Extended Data Fig. 6).  
Second, the higher prediction accuracy of PRS obtained using the full sample of GPpsy can be 
entirely explained by its larger sample size55 (113,260 cases, 219,362 controls, effective sample size = 
298,677; Supplementary Note and Extended Data Fig. 7). We calculated the effective sample size needed 
for other definitions to have the same predictive power: for strictly defined LifetimeMDD, we would need 
an effective sample size of 129,106 (Supplementary Note and Extended Data Fig. 7), less than half of that 
of GPpsy.  
Third, PRS from strictly defined LifetimeMDD predicted MDD disease status better in the 
PGC29-MDD cohorts that have a higher percentage of cases fulfilling DSM-5 symptom criteria 
(Supplementary Table 21 and Extended Data Fig. 8; Pearson r2 between AUC and percentage cases in 
PGC29-MDD cohorts fulfilling DSM-5 symptom criteria = 0.26, P = 0.025, at PRS P value threshold = 
0.1). This is consistent with the interpretation that LifetimeMDD captures signal specific to MDD. We 
did not observe such a trend for GPpsy (Pearson r = 0.02, P = 0.57 at PRS P value = 0.1) or any other 
definition of depression (Supplementary Table 23), suggesting their lower specificity for MDD.  
 
Discussion 
Our study demonstrates that the genetic architecture of minimal phenotyping definitions of depression is 
different from that of strictly defined MDD and is enriched for non-specific effects on MDD. Using a 
range of definitions of MDD in UK Biobank, from self-reported help seeking to a full assessment of the 
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DSM-5 criteria for MDD through self-reported symptoms from the MHQ, we made five key 
observations.  
First, the heritabilities of depression defined by minimal phenotyping strategies are lower than 
MDD defined by full DSM-5 criteria using the CIDI questionnaire. Second, although there is substantial 
genetic correlation between definitions, much of the shared genetic liability is not specific to MDD, and 
there remain significant differences, indicating the presence of genetic effects unique to each definition. 
Third, a larger percentage of the genome contributes to the shared genetic liability between minimal 
phenotyping definitions of depression and other psychiatric conditions than those between CIDI-based 
MDD and other conditions, likely driven by misdiagnosis due to non-specific phenotyping. Fourth, all 
GWAS hits from minimal definition of depression GPpsy are shared with genetically correlated 
conditions such as neuroticism and smoking. Finally, while minimal phenotyping definitions enable 
greater predictive power for MDD status in independent cohorts, this is due to its large sample size rather 
than its indexing of MDD-specific effects. These results point to the non-specific nature of genetic factors 
identified in minimal phenotyping definitions of depression.  
A number of factors need to be borne in mind when interpreting the above observations. 
Importantly, none of the definitions of depression in the UK Biobank were obtained from structured 
clinical interviews with an experienced rater (the gold standard for diagnosing MDD). The closest to that 
standard in UK Biobank is the online MHQ18, based on the Composite International Diagnostic Interview 
Short Form (CIDI-SF)19. Our results suggest that self-reported diagnoses using a CIDI-SF or other 
diagnostic questionnaires with full DSM-5 criteria lie on the same genetic liability continuum as MDD.  
This would argue that MDD cases identified through self-report means using a full diagnostic 
questionnaire will be enriched for more strictly defined forms, with the consequence that results from 
genetic analysis will include loci that contribute to strictly defined MDD disease risk64,65.  
Minimal definitions of MDD do not simply include cases with lower genetic liability to MDD. 
This is consistent with a recent study of three large twin cohorts, which asked if a combination of MDD, 
depressive symptoms and neuroticism is able to capture all genetic liability of MDD67, and showed that 
65% of the genetic effects contributing to MDD are specific, and minimally defined depression (inclusive 
of MDD, depressive symptoms and neuroticism) can index only around one-third of the genetic liability 
to MDD. Similarly, previously reported high degrees of genetic correlation between MDD and depressive 
symptoms (rG = 0.7, implying roughly rG2 = 49% of genetic factors contributing to liability of the former 
is attributable to that of the latter)26 need to be put in perspective of even higher degrees of sharing 
between depressive symptoms and other traits such as neuroticism (rG = 0.79-0.94, implying roughly rG2 
= 62-88% of genetic variance of the former is attributable to that of the latter, especially if both were 
assayed at a single time point66).  
11 
 
Our findings have important implications for downstream investigations. One interpretation is 
that the non-specific effects found through using minimal phenotyping approaches will still advance 
understanding of the biology of psychiatric disorders and their treatment5,56. A recent report used the 
“quasi-replication” of GWAS loci between depressive symptoms and neuroticism as validation of their 
functional significance66. An alternative view is that these loci reflect the ways in which depressive 
symptoms can develop as secondary effects, including through susceptibility to adverse life events68, 
personality types28, and use or exposure to psychoactive agents like cigarette smoking69,70—in which case, 
while useful for understanding the basis of mental ill health, they are not informative about the genetic 
etiology of MDD, and are not useful for developing disease-specific treatment.  
Our findings indicate the need for ways to integrate both strict and minimal phenotyping 
approaches to determine which loci to prioritize for follow-up functional analyses. They also indicate a 
need for means to assess symptoms for diagnosing MDD with specificity at scale, rather than reliance on 
minimal phenotyping. Fast and accurate diagnostic methods that use a limited number of questionnaire 
items are becoming available: for example, computerized adaptive diagnostic screening may be as 
effective for the diagnosis of MDD as an hour-long face-to-face clinician diagnostic interview71. There 
are ongoing attempts to convert behavioral health tracking data from phones or wearable devices into 
diagnostic information72. If successful, these attempts may lead to a dramatic expansion in our ability to 
collect data appropriate for psychiatric genetics.  
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Figure legends  
 
Figure 1 | Definitions of depression in UK Biobank. This figure shows the different definitions of 
MDD in UK Biobank and the color codings used consistently in this paper. For the minimal phenotyping 
definitions of depression presented in this paper: red for help-seeking based definitions derived from 
Touchscreen Questionnaire; blue for symptom-based definitions derived from Touchscreen 
Questionnaire; green for self-report based definition derived from Verbal Interview. For the EMR 
definition of depression: orange for definitions based on ICD10 codes. For strictly defined MDD: purple 
for CIDI-based definitions derived from Online Mental Health Followup. For the no-MDD definition: 
brown for GPNoDep, containing those cases in help-seeking definitions that do not have cardinal 
symptoms for MDD. The data fields in UK Biobank relevant for defining each phenotype are shown in 
“Data field in UK Biobank”; number of individuals with non-missing entries for each definition are 
shown in “N entries”; the qualifying answers for cases and controls respectively are shown in “Answers”; 
the case prevalences in each definition are shown in “Case Prevalence”; the study and definitions of 
depression most similar to our definitions are shown in “Most similar to”. The similarities and differences 
between help-seeking, EMR, and symptom-based definitions with definitions of depression previously 
reported can be found in the Supplementary Note.  
 
Figure 2 | Relationship between definitions of depression and environmental risk factors. a-g, These 
figures show forest plots of odds ratios (OR) and -log10 P values (LogP) between known environmental 
risk factors and different types (Category) of definitions of depression in UK Biobank (Definition) from 
logistic regression, using UK Biobank assessment center, age, sex and years of education as covariates to 
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control for potential geographical and demographic differences between environmental risk factors, 
except when they are being tested. Lifetime trauma measure was derived from Online Mental Health 
Followup (Supplementary Note and Supplementary Table 7); Townsend deprivation index, years of 
education, sex, age, recent stress and neuroticism were derived from Touchscreen Questionnaire 
(Supplementary Note). h, This figure shows a hierarchical clustering of definitions of depression in UK 
Biobank using ORs with environmental risk factors performed using the hclust function in R, “Height” 
refers to the Euclidean distance between MDD definitions at the ORs of all six risk factors. MDDRecur is 
not included in this clustering analysis as it is a subset of the LifetimeMDD definition. The statistics used 
to generate these plots are presented as Source Data. 
 
Figure 3 | SNP-heritability and genetic correlation estimates among definitions of MDD in UK 
Biobank. a, This figure shows the h2SNP estimates from PCGCs19 on each of the definitions of MDD in 
UK Biobank (Methods). h2SNP “h2(liab)” as shown on the figure has been converted to liability scale44,73 
using the observed prevalence of each definition of depression in UK Biobank as both population and 
sample prevalences (Supplementary Table 4). Error bars show the standard errors of the estimates. b, This 
figure shows the h2SNP estimates of definitions of MDD in UK Biobank from LDSC using logistic 
regression summary statistics on all SNPs > 5% MAF (Methods), transformed to the liability scale 
assuming a range of population case prevalence, from 0 to 0.5. We do not show results for case 
prevalence from 0.5 to 1, as they will be mirroring those from 0 to 0.5. In the figure, we indicate with a 
black vertical dotted line the population prevalence of 0.15, used in PGC1-MDD, and a colored vertical 
dotted line for the population prevalence of each definition of depression in UK Biobank. We also 
indicate with a black horizontal dotted line the arbitrary liability scale h2SNP of 0.2, previously estimated 
for MDD in PGC1-MDD. Using this, we show that at no prevalence would minimal phenotyping defined 
depression like GPpsy (Help-seeking definition) reach this estimate. c, This figure shows the genetic 
correlation “rG” between CIDI-based LifetimeMDD and all other definitions of MDD in UK Biobank, 
estimated using PCGCs. Error bars show the standard errors of the estimates. d, This figure shows 
pairwise rG between all definitions of depression in UK Biobank, also detailed in Supplementary Table 
15.  
 
Figure 4 | Genetic correlation between definitions of MDD and other psychiatric conditions. a, This 
figure shows the genetic correlation “rG” estimated by cross-trait LDSC46 on the liability scale between 
definitions of MDD in UK Biobank with other psychiatric conditions in both UK Biobank (smoking and 
neuroticism) and PGC47 (Supplementary Table 1), including schizophrenia53 (SCZ) and bipolar disorder54 
(BIP) (Supplementary Table 1). Error bars show the standard errors of the estimates. b, This figure shows 
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the cumulative fraction of regional genetic correlation “rG” (out of sum of regional genetic correlation 
across all loci) between definitions of MDD in UK Biobank with SCZ in 1,703 independent loci in the 
genome79 estimated using rho-HESS49, plotted against percentage of independent loci. CIDI-based 
LifetimeMDD is shown in purple while help-seeking based GPpsy is shown in red. The steeper the curve, 
the smaller the number of loci explaining the total genetic correlation. The dotted colored curves around 
each solid line represent the standard errors of the estimate computed using a jackknife approach as 
described in Shi et al.39. The dotted black line represents 100% of the sum of genetic correlation between 
each definition of MDD in UK Biobank with SCZ. The cumulative sums of positive regional genetic 
correlations (right of y axis) go beyond 100% – this is mirrored by the negative regional genetic 
correlation (left of y axis) that go below 0%. c, We rank all 1,703 loci by their magnitude of genetic 
correlation, and ask what fraction of loci sums up to 90% of total genetic correlation. This figure shows 
the percentage of loci summing up to 90% of total genetic correlation “rG” between either LifetimeMDD 
(in purple) or GPpsy (in red) with all psychiatric conditions tested, with standard errors estimated using 
the same jackknife approach. The higher the percentage, the higher the number of genetic loci 
contributing to 90% of total genetic correlation. Error bars show the standard errors of the estimates. 
 
Figure 5 | Tissue-specific gene expression enrichment in definitions of MDD. This figure shows the -
log10(P) of enrichment in h2SNP in genes specifically expressed in 44 GTEx tissues, estimated using 
partitioned h2SNP in LDSC; help-seeking based definitions of MDD GPpsy, as well as its constituent no-
MDD phenotype GPNoDep, show enrichment of h2SNP in genes specifically expressed in CNS tissues, 
similar to an independent cohort of help-seeking based MDD (23andMe4) and other psychiatric 
conditions such as bipolar disorder (BIP)54, schizophrenia (SCZ)53, autism (AUT), personality dimension 
neuroticism, and behavioural trait smoking. We indicate the sample size (N) for each definition of 
depression and psychiatric condition.  
  
Figure 6 | GWAS hits from minimal phenotyping definition of MDD in UK Biobank are not specific 
to MDD. This figure shows the odds ratios (ORs) for the risk alleles at 27 loci significantly associated 
with help-seeking based definitions of MDD in UK Biobank (GPpsy and Psypsy), in logistic regression 
GWAS conducted on CIDI (LifetimeMDD, in purple), help-seeking (GPpsy in red) and no-MDD 
(GPNoDep, in brown) based definitions of MDD. For comparison, we show the same in conditions other 
than MDD: neuroticism, smoking and SCZ (all in pink). SNPs missing in each panel are not tested in the 
respective GWAS. For clarity of display, scales on different panels vary to accommodate the different 
magnitudes of ORs of SNPs in different conditions. ORs at all 27 loci are highly consistent across 
phenotypes, being completely aligned in direction of effect, regardless of whether it is a definition or 
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MDD or a risk factor or condition other than MDD. All results are shown in Supplementary Table 14. 
Error bars show the standard errors of the estimates.   
 
Figure 7 | Out-of-sample prediction of MDD in PGC cohorts. a, This figure shows the area under the 
curve (AUC) of polygenic risk scores (PRS) calculated for each definition of depression in UK Biobank 
and MDD status indicated in 19 PGC29-MDD cohorts5, while controlling for cohort-specific effects. PRS 
were calculated using effect sizes at independent (LD r2 < 0.1) SNPs passing P value thresholds 10-4, 
0.001, 0.01, 0.05, 0.01, 0.2, 0.5 and 1, respectively, in GWAS performed on all definitions of depression 
in UK Biobank. b, This figure shows the same analysis performed on down-sampled data (7,500 cases, 
42,500 controls) for each definition of depression.  
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Online Methods 
 
Genome-wide associations. To obtain and access the difference between odds ratios of associations in 
different definitions of depression in UK Biobank, as well as smoking (data field 20160) and neuroticism 
(data field 20127), we performed logistic regression (or linear regression with --standard-beta for 
neuroticism) on all 5,276,842 common SNPs (MAF > 5% in all 337,198 White-British, unrelated 
samples) in PLINK76 (version 1.9) with 20 PCs and genotyping array as covariates.  
 
Estimation of SNP-heritability and genetic correlation among definitions of MDD. All estimates of 
h2SNP are computed with the phenotype-correlation-genotype-correlation (PCGC)77 approach implemented 
with PCGCs23, using 5,276,842 common SNPs (MAF > 5% in all 337,198 White-British, unrelated 
samples). LD scores at SNPs were computed with LDSC37 in 10,000 random samples drawn from the 
White-British samples in UK Biobank as LD reference, and MAF at all 5,276,842 common SNPs in all 
337,198 White-British samples as MAF reference. Covariates were genotyping array and 20 PCs 
computed using samples in each definition of MDD with flashPCA74. Where we stratified each definition 
of MDD in UK Biobank into two strata by risk factors such as sex (Supplementary Note), we computed 
specific PCs for each definition and strata (see also Supplementary Note and Supplementary Table 13). 
 
Estimation of genetic correlation between definitions of MDD and other conditions. Summary 
statistics for other psychiatric conditions from previous GWAS studies were obtained as described in 
Supplementary Table 1. Association summary statistics for smoking and neuroticism in UK Biobank 
were generated by GWAS (Supplementary Table 15-16 and Extended Data Fig. 3). We estimated the 
genetic correlation between definitions of MDD in UK Biobank with each of these conditions with 
LDSC46, with a LD reference panel generated with EUR individuals from 1000 Genomes78. To obtain 
regional rG, we partitioned the genome into 1,703 independent loci79 and estimated regional rG with rho-
HESS49, using a LD reference panel generated with EUR individuals from 1000 Genomes78. We 
estimated standard errors for each regional rG and the total rG across the genome using a jackknife 
approach implemented in HESS39. To assess percentage of genome contributing to total rG, we ranked all 
independent loci by their absolute value of regional rG, and asked how many loci would contribute 90% 
of the total rG. 
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Enrichment of SNP-heritability in genes specifically expressed in tissues. We estimated the 
enrichment of h2SNP in genes specifically expressed in 44 tissues in the Genotype–Tissue Expression 
(GTEx)50 project using the partitioned h2SNP framework in LDSC-SEG49, and a LD reference panel 
generated with EUR individuals from 1000 Genomes78. We obtained tissue specific gene expression 
annotations in GTEx tissues from LDSC-SEG, then estimated the enrichment of h2SNP in annotations that 
corresponded to each of the tissues together with 52 annotations in the baseline model80. We report the P 
value of the one-sided test of enrichment of h2SNP in genes specifically expressed in each tissue against the 
baseline.  
 
Out of sample predictions of MDD. We carried out out-of-sample prediction using individual level 
genotype and phenotype data from the PGC29 MDD cohorts5. We obtained permissions from 20 cohorts 
with sample sizes greater than 500, among which 17 recorded endorsement of DSM-5 criteria A for MDD 
(Supplementary Note and Supplementary Table 21). We obtained PRS from GWAS for each definition of 
depression in UK Biobank, using LD-clumped (LD r2 < 0.1) independent SNPs with P values of 
associations below 8 thresholds (P < 10-4, 0.001, 0.01, 0.05, 0.1, 0.2, 0.5 and 1), and predicted MDD 
status in the 20 PGC cohorts using the Ricopili pipeline82. We obtained Nagelkerke’s r2 between the PRS 
and MDD status, AUC of the prediction, and variance of MDD status explained by the PRS for each 
cohort. We also obtained the same measures for MDD status pulling data from all cohorts, controlling for 
cohort differences by including it as a covariate.  
 
Ethical approval. This research was conducted under the ethical approval from the UKBiobank Resource 
under application no. 28709.  
 
Reporting Summary. Additional information on the study design is provided in the Life Sciences 
Reporting Summary. 
 
Data availability  
Genotype and phenotype data used in this study are from the full release (imputation version 2) of the UK 
Biobank Resource obtained under application no. 28709. We used publicly available summary statistics 
from other studies downloadable from the website of Psychiatric Genomics Consortium 
(https://www.med.unc.edu/pgc/results-and-downloads), the references for which can be found in 
Supplementary Table 1. We also referenced the 2011 Census aggregate data from the UK Data Service 
(http://dx.doi.org/10.5257/census/aggregate-2011-2).  
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